April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Meso-Zeaxanthin Ocular Supplementation Trial: MOST
Author Affiliations & Notes
  • E. E. Connolly
    Macular Pigment Research Group, Waterford Institute of Technology, Waterford, Ireland
  • S. Beatty
    Macular Pigment Research Group, Waterford Institute of Technology, Waterford, Ireland
  • J. Loughman
    Optometry, Dublin Institute of Technology, Dublin, Ireland
  • J. M. Nolan
    Macular Pigment Research Group, Waterford Institute of Technology, Waterford, Ireland
  • Footnotes
    Commercial Relationships  E.E. Connolly, None; S. Beatty, None; J. Loughman, None; J.M. Nolan, None.
  • Footnotes
    Support  Macuvision Europe, Macuscope, Macuhealth LMZ
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 514. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E. E. Connolly, S. Beatty, J. Loughman, J. M. Nolan; Meso-Zeaxanthin Ocular Supplementation Trial: MOST. Invest. Ophthalmol. Vis. Sci. 2010;51(13):514.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : At the macula, the carotenoids meso-zeaxanthin (MZ), lutein (L) and zeaxanthin (Z) are collectively referred to as macular pigment (MP). To date only one study has reported on MP augmentation following supplementation with MZ, L and Z. However, that study measured only one retinal location (0.75°) and may not have been able to detect changes, if any, at other degrees of retinal eccentricity. Our study was designed to investigate (in a double-blind, randomized placebo controlled fashion) changes in MP optical density (MPOD, including its entire spatial profile), and serum concentrations of the macular carotenoids in response to supplemental MZ, L and Z in healthy subjects.

Methods: : We recruited 44 healthy subjects for this study. 22 subjects were randomized to consume a formulation containing 10.6 mg of MZ, 5.9 mg of L and 1.2 mg of Z (Intervention [I] group), and 22 subjects consumed a placebo everyday over a six month period (Pleacebo [P]) group). At each study visit (Baseline [V1], 3 months [V2], and 6 months [V3]) the spatial profile of MPOD (i.e. at 0.25°, 0.5°, 1° and 1.75°) was measured using customised heterochromatic flicker photometry and a blood sample was collected to analyse serum concentrations of L and Z using high performance liquid chromatography.

Results: : The mean ± SD age of our subjects was 43.54 ± 12.2. There was a statistically significant increase in serum concentrations of L and Z (µmol/L) and MPOD at 0.25° and 0.5° retinal eccentricity at V2 and V3 in the I group (p 0.05, for all).

Conclusions: : Our findings are consistent with previous supplementation studies that have shown increases in serum concentrations of L and Z and MPOD following supplementation with the macular carotenoids. Interestingly, the greatest increase seen in this study was at the centre (0.25°) following supplementation with an MZ dominant formulation.

Clinical Trial: : www.ISRCTN.org ISRCTN60816411

Keywords: macular pigment • age-related macular degeneration • antioxidants 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×